---
title: "Recordati Reports January 2026 Treasury Share Purchases Under Ongoing Buy-back Program"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/275011834.md"
description: "Recordati Industria Chimica e Farmaceutica SPA announced that UBS Europe SE executed share purchases on the Italian market as part of its ongoing buy-back program initiated in December 2025. Between January 2 and 21, 2026, UBS acquired Recordati shares at average prices of €47–49, aimed at reducing free float and enhancing shareholder value. The latest analyst rating for Recordati stock (IT:REC) is a Buy with a price target of €57.50, and the company has a market cap of €9.95B."
datetime: "2026-02-05T17:32:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275011834.md)
  - [en](https://longbridge.com/en/news/275011834.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275011834.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/275011834.md) | [繁體中文](https://longbridge.com/zh-HK/news/275011834.md)


# Recordati Reports January 2026 Treasury Share Purchases Under Ongoing Buy-back Program

### Claim 50% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Recordati Industria Chimica e Farmaceutica SPA ( (IT:REC) ) just unveiled an announcement.

Recordati disclosed that UBS Europe SE, acting as an intermediary, executed a series of purchases of Recordati shares on the Italian regulated market in January 2026 as part of the company’s ongoing share buy-back program launched in December 2025. Over multiple trading days between 2 and 21 January 2026, UBS Europe acquired tranches of Recordati treasury shares on the EXM market in Milan at average weighted prices around €47–49 per share, supporting the reduction of free float and potentially enhancing capital structure flexibility and shareholder value over time.

The most recent analyst rating on (IT:REC) stock is a Buy with a EUR57.50 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.

**More about Recordati Industria Chimica e Farmaceutica SPA**

Recordati Industria Chimica e Farmaceutica SpA (Recordati) is an Italian pharmaceutical company based in Milan, operating in the healthcare sector with a focus on prescription medicines and related pharmaceutical products, and its shares are listed on the Italian stock market.

**Average Trading Volume:** 309,952

**Technical Sentiment Signal:** Hold

**Current Market Cap:** €9.95B

See more data about REC stock on TipRanks’ Stock Analysis page.

## Related News & Research

- [The $805 monthly reality: Why the $45,859 MSRP is a 2026 trap](https://longbridge.com/en/news/281003665.md)
- [Tikehau Capital: Disclosure of Shares Repurchases from 27 March 2026 to 02 April 2026](https://longbridge.com/en/news/281621049.md)
- [Gas prices just hit their highest level since 2022—see what you’ll pay at the pump in your state](https://longbridge.com/en/news/281060631.md)
- [RE Royalties Launches Strategic Review to Maximize Shareholder Value](https://longbridge.com/en/news/281068429.md)
- [AAA: Michigan gas prices rise again](https://longbridge.com/en/news/281019895.md)